German Law Introducing Biosimilar Substitution Could Lead To Tendering
A new law in Germany could lead to tendering in the biosimilars space.
You may also be interested in...
A German bill aims to cut spending on biologics, but new revisions mean that measures on biosimilar substitution are likely to be delayed by three years.
A new bill going through the German legislative process could oblige manufacturers of orphan drugs and certain other products to submit real-world data from registries that would impact pricing.
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.